Health
Regeneron halts trial of antibody treatment in seriously ill Covid patients – Financial Times
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Regeneron has stopped enrolling seriously ill Covid-19 patients in a clinical trial of the antibody treatment that US President Donald Trump has hailed as a “cure” for the disease.
Shares in Regeneron fell as much as 3 per cent after an independent data monitoring committee warned that the risks might outweigh the benefits for hospitalised patients on high levels of oxygen.
The move comes after Eli Lilly, which is also developing a Covid-19 antibody treatment, stopped its trial in hospitalised…
-
Noosa News17 hours agoHow Lily Steele-Park took her rapist to court and won
-
General23 hours agoRush to buy homes before rate cuts send prices soaring
-
Business22 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business20 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025